Influenza is a contagious respiratory illness caused by influenza viruses, affecting millions globally each year. It accounts for approximately one billion cases of seasonal influenza annually, including 3–5 million severe cases. There is a high unmet clinical need for better therapies to treat the disease, as current treatment options, such as antivirals, have limitations in efficacy and resistance. Furthermore, the growing focus on novel influenza drugs, next-generation antivirals, and monoclonal antibodies is likely to support pipeline growth in the coming years. Advancements in influenza therapeutics, including universal vaccines and innovative antiviral agents, are anticipated to accelerate research and development efforts.
The Influenza Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into influenza therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Influenza. The influenza report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The influenza pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with influenza treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to influenza.
Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. It primarily spreads through respiratory droplets when an infected person coughs or sneezes. The virus can also survive on surfaces, facilitating transmission. Influenza occurs seasonally, with outbreaks typically taking place in colder months.
Influenza treatments focus on symptom relief and viral suppression. Antiviral medications like oseltamivir and zanamivir can reduce the severity and duration of symptoms. Vaccines, administered annually, remain the most effective preventive measure against the flu. Supportive care, including hydration and rest, is also recommended.
Influenza remains a major global health concern, with around a billion cases annually, including 3-5 million severe illnesses. The CDC estimates between 9.3 million to 41 million flu cases annually in the United States, resulting in 120,000–710,000 hospitalizations and 6,300–52,000 deaths. A United Kingdom survey of 1,000 working-age adults highlighted the widespread impact of influenza during the 2018-2022 seasons.
This section of the report covers the analysis of influenza drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total influenza clinical trials.
The drug molecule categories covered under the influenza pipeline analysis include small molecules, monoclonal antibodies, RNA-based therapies, peptides, and immunomodulators. The influenza report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for influenza.
The EMR report for the influenza drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed influenza therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in influenza clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for influenza. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of influenza drug candidates.
Ingavirin® (60 mg capsules) is being evaluated in a Phase IV clinical study sponsored by Valenta Pharm JSC to assess its efficacy and safety in treating influenza and other acute respiratory viral infections in children aged 13 to 17. The study aims to examine its therapeutic benefits compared to a placebo. Expected to be completed by December 31, 2025, it will enroll approximately 80 participants.
Baloxavir Marboxil is being investigated in a Phase IIIb surveillance study sponsored by Hoffmann-La Roche to evaluate its pre-treatment and post-treatment susceptibility in children aged 1 to <12 years with influenza. The study is expected to be completed by June 2027 and will enroll around 600 participants across multiple centers.
Zanamivir (intravenous) is being evaluated in a Phase 2 study sponsored by GlaxoSmithKline (GSK) to assess its pharmacokinetics, safety, and tolerability in hospitalized neonates and infants under six months with complicated influenza infection. The study aims to determine the drug's effectiveness and safety profile in this vulnerable population. The clinical trial is expected to be completed by December 2026 and will enroll about 12 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Influenza Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for influenza. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into influenza collaborations, regulatory environments, and potential growth opportunities.
Global Influenza Diagnostics Market
Global Influenza Vaccine Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share